Navigation Links
Mylan's Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
Date:8/18/2009

mbining numerous drugs into a once daily dose can dramatically reduce pill burden, an improvement which has been shown to enhance patient compliance with complex treatment regimens.

The FDA's tentative approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards. Although existing patents or exclusivity prevent its marketing in the U.S., the product will be eligible for purchase outside the U.S. in many developing countries.

Matrix's wide range of ARV products includes active pharmaceutical ingredients (API) and first- and second-line finished doses. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries depend on at least one Matrix ARV product.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
2. Matrixx Initiatives, Inc. Sets Time for Discussion of First Quarter Fiscal 2010 Financial Results
3. MedInsights Partners With myMatrixx(TM) for Workers Compensation Pharmacy Benefit Management
4. Matrixx Initiatives Confirms Voluntary Recall of Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Gel Swabs
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Recent FDA Action
6. Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel
7. Matrixx Initiatives, Inc. Received a Warning Letter From the Food and Drug Administration
8. Mylan Announces Successful Matrix Delisting Offer
9. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
10. Matrixx Initiatives, Inc. Reports Fiscal 2009 Revenue Increased 11% to a Record $111.6 Million and Earnings Per Share Increased 40% to $1.46
11. CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... A scientist from the University of Exeter has ... for diagnosing a frequently fatal lung disease which ... and bone marrow transplant recipients. , The lateral-flow ... invasive pulmonary aspergillosis, a notoriously difficult to diagnose ... , Invasive aspergillosis is a ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... If past experience is anything to go by, ... get a lot more recognition for their contributions to ... allowing NPs to provide primary care offer nurses more ... relationships with physicians and administrators, compared with colleagues in ... School of Nursing, published in Health Care Management ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July ... American children and teens look in the mirror and ... reported Wednesday. "Being overweight or obese is associated ... high cholesterol and diabetes," said lead researcher Neda Sarafrazi, ... Control and Prevention,s National Center for Health Statistics. ...
(Date:7/23/2014)... The next episode of “Extreme Weight Loss” Season ... physically fit through childhood and adolescence. After becoming pregnant ... decision to give her son up for adoption. That ... and she punished herself by overeating, gaining nearly 200 ... approach to weight loss transformations, “Extreme Weight Loss” airs ...
Breaking Medicine News(10 mins):Health News:New device detects deadly lung disease 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:New York law offers nurses more recognition, responsibility 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2
... Autism Speaks, the world,s largest autism science and ... top awards for "Autism Connects", the international student design ... competitors selected by a juried panel demonstrate creative technology ... better connect with the world around them, and allow ...
... News) -- People with allergies and asthma need to take ... Failure to remove contaminated materials and to reduce moisture and ... long-term health risks, according to the American College of Allergy, ... materials quickly lead to the growth of mold, a common ...
... (HealthDay News) -- Children have longer hospital stays if ... language skills, a U.S. study finds. The research, ... of Pediatrics & Adolescent Medicine , included almost 1,300 ... for treatment of infections requiring long-term antibiotics. Among ...
... 2011 The so-called "bad cholesterol" low-density lipoprotein ... shows a Texas A&M University study that casts new light on ... a researcher in the Department of Health and Kinesiology, says the ... health it has been made out to be in recent years ...
... today announced Horizon Pharma,s support of research awards ... through competition and recognition: AGA-Horizon ... $1,000 each to fellows who have submitted abstracts ... (DDW). , AGA-Horizon Pharma Student Abstract ...
... the University of North Carolina at Chapel Hill School of ... developing placenta, have given them the same properties of stem ... The scientific first opens the door for developing novel targeted ... TNBC, this is a highly recurrent tumor that spreads aggressively ...
Cached Medicine News:Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Parents' Limited English May Prolong Child's Hospital Stay 2Health News:'Bad' cholesterol not as bad as people think, shows Texas A&M study 2Health News:Horizon Pharma supports fellows and students with AGA Abstract Prizes 2Health News:Normal stem cells made to look and act like cancer stem cells 2
(Date:7/23/2014)... DALLAS , July 23, 2014 ... LLC ("Plaintiff") filed suit in the 116 ... Dallas, Texas , against RegenLab USA, ... Current and Prospective Business Relationships through false ... interference; and, Business Disparagement through libel, ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation ... generic market entry results in $5.4 billion in lost ... analysis by economic consulting firm Matrix Global ... Required by the Food and Drug ... programs are intended to improve drug safety by ensuring ...
(Date:7/23/2014)... 2014 PositiveID Corp. (OTCQB: PSID), based in ... an emerging player in the bio-threat detection market, ... and rapid medical testing. The Company,s proprietary airborne ... Networked Detector), was developed under contract with the ... Technology directorate, and $30 million of contract funding. ...
Breaking Medicine Technology:New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... Requip XL Improved Symptoms in Patients Not Optimally ... "Off" Time by Nearly Two Hours Per Day, ... (NYSE: GSK ) today announced the approval ... for the treatment,of the signs and symptoms of ...
... monotherapy study shows ACTEMRA is first and only biologic to, ... ... treatment -, PARIS, June 13 ... (RA) -- despite treatment with,current therapies -- achieved significant improvements in ...
Cached Medicine Technology:U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 2ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 3ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 4ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 6ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 7
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
... Konelab 20XT analyzer is the newest addition ... analyzers and reagents, designed to meet the ... specialty clinical laboratories. The Konelab 20XT analyzer ... 20 and yet improves on the throughput, ...
... The Shandon Coverplate is a plastic device that ... to be immunostained with a minimum amount of ... to fill the gap between the coverplate and ... until the next reagent is dispensed into the ...
Medicine Products: